Dutasteride reduces prostate cancer risk by 23% in high-risk men.
30 citations
,
January 2024 in “Frontiers in Pharmacology” These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
129 citations
,
January 2004 in “Journal of medicinal chemistry” Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.
6 citations
,
February 2016 in “Journal of Microencapsulation” Improved finasteride formula allows slow, sustained release and better absorption for patients.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
97 citations
,
December 2011 in “New England Journal of Medicine” The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
July 2004 in “Current Urology Reports” January 2015 in “INDONESIAN JOURNAL OF PHARMACY” A reliable method was developed to measure Tamsulosin and Finasteride in tablets accurately.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
March 2022 in “Research Square (Research Square)” Mushroom compounds may help treat hair loss better than Finasteride.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
January 2025 in “International Journal of Molecular Sciences” Fenugreek extract may help treat benign prostatic hyperplasia.
14 citations
,
January 2020 in “International Journal of Biological Sciences” Ranitidine and finasteride lower TMAO levels, reducing heart and kidney damage by changing gut bacteria.
January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.
1 citations
,
May 2025 in “Cytotechnology” 12 citations
,
January 2018 in “PubMed” Y-27632 helps hair follicle stem cells grow and keep their abilities.
December 2024 in “Research Journal of Pharmacy and Technology” Seablite root extract may help prevent hair loss and promote hair growth.
4 citations
,
August 2021 in “Annals of Translational Medicine” Dihydroartemisinin helps reduce prostate enlargement in rats by stopping the growth of prostate cells.
1 citations
,
April 2025 in “Drug Delivery and Translational Research” 13 citations
,
March 1999 in “Biochemical Journal” Overexpressing SSAT in mice makes them highly sensitive to polyamine analogues, causing liver damage and high mortality.
1 citations
,
August 2024 in “Indian Dermatology Online Journal” Bicalutamide may effectively treat female pattern hair loss with minimal side effects.
November 2025 in “Journal of Dermatological Treatment” Dexamethasone oral mini-pulse therapy effectively treats severe alopecia areata when JAK inhibitors can't be used.
7 citations
,
January 2019 in “Dermatology Online Journal” Ustekinumab treatment didn't prevent frontal fibrosing alopecia.
156 citations
,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
2 citations
,
June 2012 in “Digestive Diseases and Sciences” Finasteride and methadone don't increase advanced liver disease risk in HCV+ male veterans.
June 2026 in “The Pharmacogenomics Journal”
69 citations
,
August 2008 in “Journal of The European Academy of Dermatology and Venereology” Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.